Aclaris Therapeutics, Inc. - 8-K Filing

Aclaris Therapeutics reports Phase 2 ADMIRATION trial failure for bosakitug in atopic dermatitis while initiating modzatinib Phase 2b ALPHA trial. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $ACRS

Read the full article at SEC EDGAR

Part of the story Aclaris Therapeutics, Inc. - 8-K Filing (3 articles)

More Regulatory news